In parallel, an alternate fully human immunoglobulin G (IgG)2 mAb, panitumumab, combined with neoadjuvant chemotherapy (NCT), exhibited considerable efficacy in a single-arm phase II study involving HER2-negative inflammatory breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.